Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Clin Cancer Res. 2022 Jan 15;28(2):429. doi: 10.1158/1078-0432.CCR-21-4241.
No abstract available

Publication types

  • Published Erratum